Gonadorelin Research Guide

Gonadorelin BAC Water & Reconstitution Guide

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), the hypothalamic peptide that regulates pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). There is no single universal BAC-water volume for gonadorelin: the liquid volume selected for a research preparation determines the resulting concentration.

Research Reference Human Clinical Evidence Exists Historical U.S. Human Products
Chemical structure of gonadorelin
Gonadorelin chemical structure. Image source: Wikimedia Commons, public-domain structural image.

Gonadorelin Research Snapshot

Compound Gonadorelin
Class Synthetic GnRH / decapeptide
Research Category Reproductive endocrinology
Molecular Weight Approximately 1,182.3 Da
Human Regulatory History Historical FDA approvals; products discontinued
Current FDA Gonadorelin Products Current U.S. labels located are veterinary
Historical Human Vials 0.1 mg, 0.2 mg, 0.5 mg, 0.8 mg, 3.2 mg
Evidence Level Human clinical research available
Last Reviewed September 10, 2026

How Much BAC Water for Gonadorelin?

There is no scientifically established universal BAC-water volume that applies to every gonadorelin preparation. The amount of liquid changes the concentration of the resulting solution, while the total amount of gonadorelin contained in the vial remains unchanged.

Concentration = Total Gonadorelin Quantity ÷ Liquid Volume

For example, a mathematical preparation containing 1 mg of gonadorelin in 1 mL would have a concentration of 1 mg/mL. The same 1 mg quantity in 2 mL would produce 0.5 mg/mL.

These are concentration calculations only. They are not dosing instructions, treatment recommendations, or a recommendation that any particular volume of bacteriostatic water should be used.

Gonadorelin Concentration Examples by Vial Quantity

The vial quantities below include historical gonadorelin presentations documented in FDA records. They should not be interpreted as currently marketed human products. The table simply demonstrates how different liquid volumes mathematically change concentration.

Vial Quantity 1 mL 2 mL 2.5 mL 3 mL 5 mL
0.1 mg 0.10 mg/mL 0.05 mg/mL 0.04 mg/mL 0.033 mg/mL 0.02 mg/mL
0.2 mg 0.20 mg/mL 0.10 mg/mL 0.08 mg/mL 0.067 mg/mL 0.04 mg/mL
0.5 mg 0.50 mg/mL 0.25 mg/mL 0.20 mg/mL 0.167 mg/mL 0.10 mg/mL
0.8 mg 0.80 mg/mL 0.40 mg/mL 0.32 mg/mL 0.267 mg/mL 0.16 mg/mL
3.2 mg 3.20 mg/mL 1.60 mg/mL 1.28 mg/mL 1.067 mg/mL 0.64 mg/mL
Important concentration distinction:

Increasing the liquid volume produces a lower concentration. Decreasing the liquid volume produces a higher concentration. Neither calculation establishes a clinically appropriate dose, administration volume, or reconstitution procedure.

Need a different vial quantity or BAC-water volume?

Use the BacScience calculator for custom mathematical concentration calculations.

Open BAC Water Calculator

How Much BAC Water Should Be Added to Gonadorelin?

Short answer: there is no single universal amount. The appropriate mathematical liquid volume depends on the desired concentration and the total quantity of gonadorelin represented by the material being studied.

A product-specific preparation should only follow the instructions supplied with that particular research material or an authoritative laboratory protocol. A generic BAC-water calculation should not be confused with product-specific sterility, stability, compatibility, or administration instructions.

How does BAC-water volume change gonadorelin concentration?

Concentration is inversely related to liquid volume when the total compound quantity stays constant. For example, 0.5 mg distributed mathematically across 1 mL produces 0.5 mg/mL, while the same 0.5 mg across 5 mL produces 0.1 mg/mL.

How do you calculate gonadorelin concentration?

Divide the total amount of gonadorelin by the final liquid volume. Keep the units consistent before performing the calculation.

What Is Gonadorelin?

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a hypothalamic decapeptide involved in regulation of the reproductive endocrine axis. Gonadorelin has the same core amino-acid sequence as endogenous GnRH.

The peptide acts primarily through GnRH receptors in the anterior pituitary. GnRH signaling stimulates secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

FDA documentation describes gonadorelin as the hypothalamic releasing hormone responsible for release of LH and FSH. Historical FDA records also document human gonadorelin products, while current FDA-listed gonadorelin injection products include veterinary formulations.

Gonadorelin and the GnRH Signaling System

Gonadorelin is the native GnRH peptide rather than a long-acting GnRH analogue. Its physiological signaling is strongly influenced by pulsatile release from the hypothalamus.

This distinction matters when interpreting research because native GnRH/gonadorelin and longer-acting GnRH agonists or antagonists can produce substantially different endocrine effects.

Three dimensional structure of gonadotropin releasing hormone
Three-dimensional structure of GnRH based on PDB structure 1YY1. Image source: Wikimedia Commons.

How Gonadorelin Works

Step 01
GnRH Receptor Activation

Gonadorelin binds to GnRH receptors on pituitary gonadotroph cells.

Step 02
LH and FSH Release

GnRH receptor signaling stimulates release of LH and FSH from the anterior pituitary.

Step 03
Reproductive Axis Signaling

LH and FSH participate in downstream regulation of gonadal steroidogenesis and reproductive function.

Pulsatility matters.

Endogenous GnRH is released in pulses. Clinical and experimental research involving gonadorelin therefore often evaluates pulsatile administration rather than treating gonadorelin as interchangeable with long-acting GnRH agonists.

What Is Gonadorelin Being Studied For?

Hypogonadotropic Hypogonadism

Published human research has examined pulsatile GnRH/gonadorelin treatment in people with hypothalamic or hypogonadotropic reproductive disorders.

Ovulation and Reproductive Research

Historical clinical studies investigated pulsatile GnRH in women with hypothalamic amenorrhea and related reproductive disorders.

Endocrine Diagnostic Research

Gonadorelin has also been investigated as a pharmacological stimulus for evaluating pituitary gonadotropin responses.

Experimental Endocrinology

Current literature continues to investigate how pulsatile GnRH signaling affects LH, FSH, testosterone, estradiol and reproductive outcomes in specific populations.

Human Clinical Research

Gonadorelin has a substantial historical human research record. However, evidence from a particular clinical population should not automatically be converted into a generalized research protocol or treatment recommendation.

Research Context Population Administration Pattern Reported Research Finding
Pulsatile GnRH Men with congenital hypogonadotropic hypogonadism 7–15 μg per pulse every 90 minutes in one retrospective study Gonadotropins and testosterone increased; spermatogenesis was observed in a subset.
Pulsatile GnRH Women with idiopathic hypogonadotropic hypogonadism 10 μg per 90-minute pulse in a small retrospective study Changes in LH, FSH and estradiol were reported, with menstrual recovery in several participants.
Diagnostic stimulation Women evaluated for gonadotropin response Historical intravenous gonadorelin testing Gonadotropin responses were measured after pharmacological stimulation.
Research-dose warning:

The values in this section are doses or administration patterns reported in published research. They are included for scientific context only and are not BacScience dosage recommendations.

Preclinical Research

Gonadorelin has also been used in animal reproductive research, including studies examining ovulation, follicular dynamics and reproductive synchronization.

Animal studies should not be treated as direct evidence for human dosing, safety, preparation volume or clinical effectiveness. Species, formulation, route, timing and endocrine physiology can all materially affect the result.

Research Reconstitution & Concentration

When a research compound is supplied as a dry material, concentration calculations require knowing the total quantity of compound and the final liquid volume. The basic mathematical relationship is:

Concentration = Total Compound Quantity ÷ Final Liquid Volume

Example: 0.5 mg ÷ 2 mL = 0.25 mg/mL.

Example calculation

If a hypothetical research vial contains 0.5 mg of gonadorelin and the final liquid volume is mathematically set at 2 mL:

0.5 mg ÷ 2 mL = 0.25 mg/mL

This calculation describes concentration only. It does not establish whether 2 mL is an appropriate reconstitution volume, whether bacteriostatic water is compatible with a particular formulation, whether the material is sterile, or whether the resulting preparation is suitable for administration.

BAC Water vs. Gonadorelin Concentration

More Liquid

Adding a greater volume of diluent lowers the calculated concentration when the total quantity of gonadorelin remains constant.

Example: 0.5 mg ÷ 5 mL = 0.10 mg/mL.

Less Liquid

Using a smaller final liquid volume produces a higher calculated concentration when the total amount of gonadorelin remains constant.

Example: 0.5 mg ÷ 1 mL = 0.50 mg/mL.

Do not confuse concentration with dose.

Concentration describes the amount of compound per unit of liquid. Dose describes an amount administered to a subject. These concepts are mathematically and scientifically different.

Gonadorelin Regulatory Status

FDA records document historical human gonadorelin products. The FDA Orphan Drug database records gonadorelin acetate under the historical Lutrepulse product, with a marketing approval date of October 10, 1989.

The FDA Orange Book's discontinued-product list documents historical gonadorelin acetate Lutrepulse presentations at 0.8 mg/vial and 3.2 mg/vial, and historical gonadorelin hydrochloride Factrel presentations equivalent to 0.1 mg, 0.2 mg and 0.5 mg of base per vial.

Current DailyMed/FDA records for products containing gonadorelin, including Factrel and Cystorelin, describe veterinary products. Therefore, current veterinary labels should not be presented as human gonadorelin reconstitution instructions.

Regulatory distinction:

Historical FDA approval does not mean that a corresponding human gonadorelin product is currently marketed in the United States. Conversely, a currently marketed veterinary gonadorelin product does not establish human approval or human use.

Research Limitations & Safety

  • This page is educational and research-oriented.
  • Mathematical concentration examples are not medical dosing recommendations.
  • Historical clinical doses should not be converted into generalized modern protocols.
  • Veterinary gonadorelin products should not be assumed to be suitable for human research or administration.
  • BAC water should not automatically be assumed to be compatible with every gonadorelin research material or formulation.
  • Sterility, pH, excipients, stability, container compatibility and storage requirements are formulation-specific considerations.
  • If a specific research material has manufacturer or laboratory preparation instructions, those instructions should be evaluated independently rather than replaced by a generic calculator.
Important:

No universal gonadorelin BAC-water volume has been established by the sources reviewed for this page. The concentration examples above are mathematical demonstrations rather than instructions for preparing or administering gonadorelin.

BAC Water Calculator

Calculate mathematical concentration relationships using a custom vial quantity and liquid volume.

Open BAC Water Calculator →

Peptide Research Library

Explore research-oriented information about peptide compounds, mechanisms, evidence levels and concentration calculations.

Explore Peptide Research Library →

BAC Water Research

Review educational resources covering bacteriostatic water, sterility, benzyl alcohol and research preparation principles.

Explore BAC Water Research →

Testing & Transparency

Learn about analytical testing, certificates of analysis, batch traceability and research-material transparency.

Explore Testing & Transparency →

Frequently Asked Questions About Gonadorelin BAC Water

How much BAC water should be added to gonadorelin?

There is no universal volume. The liquid volume determines the mathematical concentration, while product-specific preparation requirements depend on the particular formulation and research protocol.

What is the formula for gonadorelin concentration?

Concentration equals total gonadorelin quantity divided by final liquid volume. For example, 0.5 mg divided by 2 mL equals 0.25 mg/mL.

Does adding more BAC water make gonadorelin weaker?

Mathematically, yes. With the same total amount of gonadorelin, increasing the liquid volume decreases the concentration per mL.

Does adding less BAC water increase concentration?

Mathematically, yes. A smaller liquid volume produces a higher amount of gonadorelin per mL when the total compound quantity is unchanged.

Is BAC water the same as sterile water?

No. Bacteriostatic water and sterile water are different formulations. Bacteriostatic water typically contains a bacteriostatic preservative, while sterile water does not necessarily contain the same preservative system.

Is gonadorelin FDA approved?

FDA records document historical human gonadorelin approvals, including Lutrepulse and Factrel, but the historical human products are listed as discontinued. Current FDA-listed gonadorelin injection products located in the reviewed sources are veterinary products.

What are the historical gonadorelin vial sizes?

FDA Orange Book records document historical Factrel presentations equivalent to 0.1 mg, 0.2 mg and 0.5 mg gonadorelin base per vial, and historical Lutrepulse presentations at 0.8 mg and 3.2 mg per vial.

What has gonadorelin been studied for?

Human research has examined gonadorelin in contexts including hypogonadotropic hypogonadism, hypothalamic amenorrhea, reproductive endocrinology and diagnostic stimulation of pituitary gonadotropin responses.

Is gonadorelin the same as a long-acting GnRH agonist?

No. Gonadorelin is native GnRH, whereas compounds such as leuprolide are GnRH agonist analogues with different pharmacological properties and exposure patterns.

Are research doses of gonadorelin medical recommendations?

No. Published research doses describe what investigators used in specific studies and populations. They should not be presented as generalized dosing recommendations.

Can the BacScience calculator determine a gonadorelin dose?

No. The calculator is intended for mathematical concentration calculations based on compound quantity and liquid volume. It does not determine a clinically appropriate dose or validate a formulation.

Where can I calculate a different gonadorelin concentration?

Use the BacScience BAC Water Calculator to perform custom concentration calculations.

Scientific References

  1. U.S. Food and Drug Administration. Orange Book — Discontinued Drug Product List. Historical gonadorelin acetate and gonadorelin hydrochloride presentations.
  2. U.S. Food and Drug Administration. Orphan Drug Designations and Approvals — Gonadorelin acetate / Lutrepulse. Historical FDA approval information.
  3. U.S. FDA / DailyMed. FACTREL — Gonadorelin Hydrochloride Injection. Current veterinary labeling and compound identity information.
  4. U.S. FDA / DailyMed. CYSTORELIN — Gonadorelin Injection. Current veterinary formulation information.
  5. Kliesch S, Behre HM, Nieschlag E. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. European Journal of Endocrinology. 1994.
  6. Effectiveness and safety of pulsatile GnRH pump therapy on female patients with idiopathic hypogonadotropic hypogonadism. PubMed-indexed clinical research.
  7. Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. PubMed-indexed clinical research.
  8. Wikimedia Commons. Gonadorelin.svg. Chemical structure of gonadorelin.
  9. Wikimedia Commons. GNRH 1YY1.png. Three-dimensional GnRH structure based on PDB 1YY1.
Last Scientifically Reviewed: September 10, 2026
Content Type: Educational research reference
Medical Status: Not a treatment or dosing recommendation